China Clears HIV Oral Antiviral For COVID, Vows More Drug Approvals
As the Communist Party of China gears up for its once in every five years National Congress late this fall, the need for more novel drugs to help address the persistent coronavirus pandemic is rising amid the country’s strict “COVID Zero” policies.
You may also be interested in...
China’s Center for Drug and Evaluation has issued new guidance on the development of new vaccines and drugs for COVID-19 in which it backs antivirals as a key weapon, while the Politburo has shown no signs of backing away from the country's tough "COVID Zero" policies.
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.
Six months after Brii obtained Chinese approval for its antibody combo for COVID-19, the Beijing joint venture finally launches the drug in China.